Every controlled substance that leaves an automated dispensing cabinet follows one of three documented paths:
- Administration to the patient
- Return to the dispensing cabinet or pharmacy
- Waste of the unused portion
Of those three, waste is the least scrutinized and the most exploited. Bluesight’s Diversion Trends Report recorded over 16 million wasted packages across its hospital network, totaling roughly $38 million in lost costs. Nearly a quarter of those packages contained fentanyl, the same drug that topped the list for transaction variances.
Most compliance programs concentrate their surveillance on dispensing and administration discrepancies. Narcotic wasting inconsistencies, meanwhile, surface earlier and more reliably than almost any other diversion signal. A structured, data-driven approach to ‘wasting’ gives compliance teams the ability to flag high-risk behavior before it becomes a confirmed diversion event.
Why Narcotic Wasting Creates a Compliance Blind Spot
When a clinician administers a partial dose of a controlled substance, they must document the disposal of the remaining amount, typically at the ADC, with a second clinician serving as a witness. This witnessed wasting process is designed to create accountability, but it also creates opportunity. Diverters routinely record pilfered drugs as “waste,” exploiting the trust-based nature of the witness system and the time pressure their colleagues face on the floor.
The regulatory stakes are well established:
- The DEA requires controlled substances to be rendered “non-retrievable” upon disposal under 21 CFR Part 1317.
- CMS Conditions of Participation mandate complete records from procurement through administration, waste, or return (42 CFR §482.25).
- The Joint Commission holds institutions responsible for appropriate wasting, documentation, and oversight.
- The 2022 ASHP Guidelines on Preventing Diversion call for regular review of wasting practices as a core diversion program component.
Despite all of this, half of all transaction variances in Bluesight’s dataset were flagged because of incorrect documentation:
- Mischarting
- Wrong patient
- Wrong drug
- Wrong dosage
That gap between regulatory expectation and operational reality is exactly where diversion hides.
Six Wasting Patterns That Signal Diversion Risk
Not every documentation inconsistency points to diversion. Some reflect the realities of a demanding clinical environment. These patterns become meaningful when they cluster around a single individual or persist over time. Compliance teams should monitor for these six signals as part of any controlled substance tracking program.
| Wasting Pattern | What It Looks Like | Why It Matters |
| High-volume wasting relative to peers | A clinician consistently wastes more controlled substances than colleagues in the same care area and role. | Excessive wasting can mask the removal of drugs under the guise of partial-dose disposal. |
| Repeated use of the same waste witness | One clinician appears as the witness for a disproportionate share of another’s waste events. | Diverters often rely on a single trusted colleague to avoid scrutiny. Concentrated pairings in waste witness networks deserve closer review. |
| Wasting when smaller doses were available | A clinician pulls a larger vial than the ordered dose requires, then wastes the excess. | When unit-dose options exist, choosing a larger vial and wasting the remainder creates an opportunity to pocket the difference. |
| Delayed or end-of-shift wasting | Waste documentation occurs long after dispensing, or multiple waste events are batched at the end of a shift. | A time gap between dispensing and documented wasting may indicate the substance was never disposed of at the point of care. |
| Disproportionate wasting of high-value narcotics | A clinician’s waste events skew heavily toward fentanyl, hydromorphone, or midazolam relative to peers. | Fentanyl accounted for 24% of variances in Bluesight’s data, followed by midazolam at 15% and hydromorphone at 10%. |
| Forged or unconfirmed witness signatures | A named waste witness reports they did not observe the disposal, or the witness’s initials were added without their knowledge. | This indicates either expediency or intentional falsification, both of which violate federal law regardless of the underlying intent. |
Any one of these patterns in isolation may have an innocent explanation. When two or three converge around the same clinician, the probability of diversion rises sharply.
How to Build a Data-Driven Wasting Analysis Framework
Moving from reactive spot-checks to proactive surveillance requires a systematic approach. These six steps turn raw transaction data into actionable intelligence.
Aggregate and Integrate Data Sources
Controlled substance tracking depends on visibility across systems. Siloed data prevents the kind of cross-referencing that reveals patterns. A centralized view should pull from:
- Automated dispensing cabinets (ADCs)
- Electronic health records (EHRs)
- Time-and-attendance records
- Controlled substance vault logs
Establish Peer-Group Benchmarks
Facility-wide averages obscure meaningful variation. Compare wasting behavior within comparable groups:
- Same department
- Same role
- Same care area
A cardiac ICU nurse’s wasting profile will look different from a pediatric floor nurse’s, and benchmarks that ignore that context generate noise instead of signal.
Apply Outlier Detection Beyond Simple Averages
Standard deviations and basic averages miss sophisticated diverters who stay close enough to the mean to avoid detection. Machine learning algorithms can evaluate distance and variation from peer norms across multiple variables simultaneously:
- Waste volume
- Witness networks
- Timing between transactions
- Drug type
- Location and mobility
Prioritize With Composite Risk Scoring
A single metric rarely tells the full story. Composite risk scores rank individuals by the convergence of multiple anomalous signals. Bluesight’s Individual Risk Identification Score (IRIS) uses data from waste networks, dispense trends, shift analysis, and other reports to compare individuals against their hospital, care area, and department.
Move to Continuous Monitoring
Monthly retrospective reports leave too much time between a diversion event and its detection. Real-time or near-real-time surveillance shortens that window. Bluesight’s data shows that hospitals using improved monitoring workflows closed investigations 37 days faster on average, dropping from 84 days in early 2022 to 47 days by the end of 2023.
Define an Escalation Protocol
Every flagged pattern needs a documented path with an audit trail at each step:
- Initial review
- Deeper analysis
- Formal investigation
- Resolution and reporting
The DEA expects facilities to report theft or significant loss within one business day of discovery, and CMS requires that diversion and loss be reported to the individual responsible for pharmaceutical services.
Why Narcotics Tracking Software Changes the Equation
Manual review of wasting transactions does not scale. Hospitals generate thousands of controlled substance transactions daily, and spot-checking a small sample leaves the vast majority of activity unexamined. That approach worked when diverters were less sophisticated. It does not work now.
Narcotics tracking software like Bluesight’s ControlCheck automates closed-loop dose reconciliation, tracing each dispense through its corresponding administration, waste, or return. The platform automatically reconciles 95% of transactions, freeing compliance teams to focus on the anomalies that carry genuine risk. Its machine learning algorithms surface behavioral differences that manual reviews cannot detect, including waste-witness relationships, location patterns, and the time elapsed between transaction events.
ControlCheck has earned Best in KLAS recognition five times for Drug Diversion Monitoring and detects diversion 6.6x more effectively than other next-generation solutions. For pharmacy leaders and compliance teams already stretched thin, the right narcotics tracking software does not add to the workload. It focuses on the workload where risk is highest.
Narcotic Waste Data Is a Leading Indicator, Not a Lagging One
Regulatory expectations from the DEA, CMS, and accrediting bodies continue to tighten. The DEA launched a hospital initiative in 2025 focused specifically on educating facilities about regulatory requirements and best practices for preventing diversion. Hospitals that treat narcotic waste analysis as a proactive surveillance tool, rather than a compliance checkbox, will be better positioned to protect patients, support their workforce, and maintain regulatory standing.
Bluesight’s 2024 Diversion Trends Report provides benchmark data from over 127 million controlled substance transactions across 794 hospitals. Download the full report to see how your program compares, or request a ControlCheck demo to see how automated wasting analysis works in practice.